Search Results

Sparrow Pharmaceuticals will present interim results from a Phase 2 clinical trial of its novel HSD-1 inhibitor, clofutriben (SPI-62), administered in combination with prednisolone to patients with polymyalgia rheumatica, at the European Congress of Rheumatology (EULAR) 2024 congress in Vienna, Austria during a highlighted session, “The 75th Anniversary of Glucocorticoids - what have we learnt?”

After four patient deaths, Kezar’s lupus trial is officially on hold, sparking investor Kevin Tang’s interest for acquisition.

Zylö recently effected a spinout of Atticus Pharma Inc., whose mission is to unlock the value of the Z-pod ® topical delivery platform in the pharmaceutical vertical.

Astellas Pharma’s new life sciences center houses its first U.S.-based SakuLab, an incubator space for external partners, as well as its engineered small molecules unit.

Big Pharma had plenty of drama to keep journalists busy this quarter, which painted an accurate portrait of the wild and wonderful world of biopharma.

Kane Biotech Inc. announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB ® technology.

Agile Therapeutics, Inc. today announced that it has entered into a definitive merger agreement (“Merger Agreement”) with Insud Pharma, S.L.

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.